Insider filing
Traded Mar 31 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 2, 2026 · Filed Mar 3, 2026
AbbVie's GC AND SECRETARY sold $2.41M of AbbVie shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$2,414,886
Shares × reported transaction price
26 days after results of Feb 4, 2026, 32 days before results of Apr 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $234.26 on Mar 2, 2026, within 5% of its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $170.16 (Apr 21, 2025) to $244.38 (Oct 1, 2025), 86% of the way up, from 251 adjusted closes. 30 trading days earlier: $216.75 on Jan 15, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Skyrizi on Mar 6, 2026, 4 days after this trade.
New use approved (efficacy supplement). Active ingredient: Risankizumab-Rzaa. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.6% | −1.3% | −2.3% |
| 30 days | −12.5% | −3.8% | −8.7% |
| 90 days | −8.8% | +10.9% | −19.7% |
| 180 days | +8.6% | +12.0% | −3.4% |
Past results only. Not a forecast.
Insider filing
Traded Mar 31 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 31 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 31 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.